Klaus F Rabe

May 20, 2024 | nejm.org | Surya P. Bhatt |Klaus F Rabe |Nicola Hanania |Claus Vogelmeier

Published May 20, 2024DOI: 10.1056/NEJMoa2401304 For permission requests, please contact NEJM Reprints at [email protected] article was published on May 20, 2024, at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by Sanofi and Regeneron Pharmaceuticals. Dr. Singh is supported by the National Institute for Health Research Manchester Biomedical Research Centre.

Nov 1, 2023 | openres.ersjournals.com | Juby Jacob-Nara |Christian Domingo |Klaus F Rabe |David Price

IntroductionOral corticosteroids (OCS) are commonly used for asthma management, particularly in patients with severe or uncontrolled disease [1]. However, OCS use is associated with increased risk of both acute adverse events and chronic adverse effects, including metabolic, bone- and muscle-related, cardiovascular and psychiatric complications [2, 3].